A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Ku, Hsun Teresa, Ph.D. Research Bookmark and Share

Hsun Teresa Ku, Ph.D. Research

Identification and Characterization of Pancreatic Stem Cells
A functional pancreas consists of two types of tissue: exocrine and endocrine. The exocrine tissue mainly consists of acinar cells, which secrete bicarbonate and digestive enzymes. These secretions are collected by the pancreatic ductal system, which begins with centroacinar cells that are directly in contact with acinar cells. The prolongation of the terminal ducts, or alveoli, are lined by centroacinar cells and gradually merge into a main duct that drains into the duodenum. The endocrine tissue is organized as islets and contains cells that secrete glucagon, insulin, somatostatin, pancreatic polypeptide or grehlin. These endocrine hormones are released directly into the blood stream in response to metabolic signals.
 
Recently, there has been an intense interest in identifying pancreatic stem or progenitor cells, especially the endocrine progenitor cells, for the purpose of replacement therapy of Type 1 diabetes (T1D), a disease in which the insulin-secreting beta cells are specifically destroyed by autoimmunity. However, the existence of self-renewing multipotential stem cells in the pancreas remains elusive. Our laboratory is interested in the identification and characterization of pancreatic stem/progenitor cells, using both mouse models and cadaverous human pancreatic tissues for studies. We have established a quantitative and clonogenic progenitor cell assay in our laboratory, which will be a powerful tool to study the cellular and molecular mechanisms that govern the differentiation and proliferation of the pancreatic stem/progenitor cells at the single cell level.
 
Embryonic Stem Cell Therapy for Type 1 Diabetes
T1D is marked by a deficiency of the insulin-secreting β cells residing in the Islets of Langerhans within the pancreas due to autoimmune destruction. One of the long-term goals of our laboratory is to advance clinical cell-replacement therapy for patients with sever forms of T1D by developing a safe, reliable and abundant source of cells, derived from human stem cells that function like pancreatic islets. Toward this end, we have established an efficient and potentially cost-effective differentiation protocol, originally adapted from a mouse embryonic stem cell (ESC) differentiation method previously established in our laboratory, and generated a population of glucose-responsive, insulin-producing and secreting cells derived from human ESCs while in vitro. This cell population will be a suitable development candidate for clinical cell replacement therapy for T1D at City of Hope in the future.
 
Embryonic Stem Cells as a Cellular Tool for Screening of Molecules for Treatment of Diabetes
In the small molecule drug discovery field, the “bottom-up” approach, which is based on structural considerations of known targets, has not been as fruitful as was once promised. ESC technology ffers a potential solution to this bottleneck. ESCs can be grown in large numbers and maintained in a pluripotent state in vitro. They can also be induced in culture to differentiate into cells from all three germ layers in a relatively normal fashion that is faithful to development in vivo. Three properties make ES cells an ideal platform for drug discovery: first, ES cells can provide virtually inexhaustible quantities of target cells, which is necessary for screening of large numbers of compounds; second, ES cells can differentiate into mature cells with phenotypes that mimic their counterparts in vivo; and third, compared with immortalized cell lines, ES cells and their derivatives will provide a much more accurate platform for the “top-down” drug screening approach. Our laboratory is interested in high throughput screening (HTS) of small molecules that may affect proliferation, differentiation and/or maturation of the pancreatic insulin-producing  β cells and their immediate progenitors. We have established a relatively simple and inexpensive differentiation protocol that allows efficient generation of the pancreatic like, insulin-expressing cells from murine ESCs. Thus, this ESC to pancreatic lineage differentiation assay will be valuable to serve as a cellular tool for screening large number of molecules that could be used to treat diabetes.
 
 
 

H. Teresa Ku, Ph.D. Lab Members

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H. Teresa Ku, Ph.D.
Professor
626-256-HOPE (4673), ext. 61174
 
Jeanne LeBon, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 63796
 
Dan Gao, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 62251
 
Liang Jin, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 61449
 
Lena Wedeken, Ph.D.,
Postdoctoral Fellow and a CIRM Postdoctoral Scholar
626-256-HOPE (4673), ext. 33242
 
Stephanie Walker, B.S.
Research Associate I
626-256-HOPE (4673), ext. 31235
 
Nadiah Ghazalli, M.S.
Graduate Student and a CIRM Predoctoral Scholar
626-256-HOPE (4673), ext. 31235
 

Ku, Hsun Teresa, Ph.D. Research

Hsun Teresa Ku, Ph.D. Research

Identification and Characterization of Pancreatic Stem Cells
A functional pancreas consists of two types of tissue: exocrine and endocrine. The exocrine tissue mainly consists of acinar cells, which secrete bicarbonate and digestive enzymes. These secretions are collected by the pancreatic ductal system, which begins with centroacinar cells that are directly in contact with acinar cells. The prolongation of the terminal ducts, or alveoli, are lined by centroacinar cells and gradually merge into a main duct that drains into the duodenum. The endocrine tissue is organized as islets and contains cells that secrete glucagon, insulin, somatostatin, pancreatic polypeptide or grehlin. These endocrine hormones are released directly into the blood stream in response to metabolic signals.
 
Recently, there has been an intense interest in identifying pancreatic stem or progenitor cells, especially the endocrine progenitor cells, for the purpose of replacement therapy of Type 1 diabetes (T1D), a disease in which the insulin-secreting beta cells are specifically destroyed by autoimmunity. However, the existence of self-renewing multipotential stem cells in the pancreas remains elusive. Our laboratory is interested in the identification and characterization of pancreatic stem/progenitor cells, using both mouse models and cadaverous human pancreatic tissues for studies. We have established a quantitative and clonogenic progenitor cell assay in our laboratory, which will be a powerful tool to study the cellular and molecular mechanisms that govern the differentiation and proliferation of the pancreatic stem/progenitor cells at the single cell level.
 
Embryonic Stem Cell Therapy for Type 1 Diabetes
T1D is marked by a deficiency of the insulin-secreting β cells residing in the Islets of Langerhans within the pancreas due to autoimmune destruction. One of the long-term goals of our laboratory is to advance clinical cell-replacement therapy for patients with sever forms of T1D by developing a safe, reliable and abundant source of cells, derived from human stem cells that function like pancreatic islets. Toward this end, we have established an efficient and potentially cost-effective differentiation protocol, originally adapted from a mouse embryonic stem cell (ESC) differentiation method previously established in our laboratory, and generated a population of glucose-responsive, insulin-producing and secreting cells derived from human ESCs while in vitro. This cell population will be a suitable development candidate for clinical cell replacement therapy for T1D at City of Hope in the future.
 
Embryonic Stem Cells as a Cellular Tool for Screening of Molecules for Treatment of Diabetes
In the small molecule drug discovery field, the “bottom-up” approach, which is based on structural considerations of known targets, has not been as fruitful as was once promised. ESC technology ffers a potential solution to this bottleneck. ESCs can be grown in large numbers and maintained in a pluripotent state in vitro. They can also be induced in culture to differentiate into cells from all three germ layers in a relatively normal fashion that is faithful to development in vivo. Three properties make ES cells an ideal platform for drug discovery: first, ES cells can provide virtually inexhaustible quantities of target cells, which is necessary for screening of large numbers of compounds; second, ES cells can differentiate into mature cells with phenotypes that mimic their counterparts in vivo; and third, compared with immortalized cell lines, ES cells and their derivatives will provide a much more accurate platform for the “top-down” drug screening approach. Our laboratory is interested in high throughput screening (HTS) of small molecules that may affect proliferation, differentiation and/or maturation of the pancreatic insulin-producing  β cells and their immediate progenitors. We have established a relatively simple and inexpensive differentiation protocol that allows efficient generation of the pancreatic like, insulin-expressing cells from murine ESCs. Thus, this ESC to pancreatic lineage differentiation assay will be valuable to serve as a cellular tool for screening large number of molecules that could be used to treat diabetes.
 
 
 

Lab Members

H. Teresa Ku, Ph.D. Lab Members

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H. Teresa Ku, Ph.D.
Professor
626-256-HOPE (4673), ext. 61174
 
Jeanne LeBon, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 63796
 
Dan Gao, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 62251
 
Liang Jin, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 61449
 
Lena Wedeken, Ph.D.,
Postdoctoral Fellow and a CIRM Postdoctoral Scholar
626-256-HOPE (4673), ext. 33242
 
Stephanie Walker, B.S.
Research Associate I
626-256-HOPE (4673), ext. 31235
 
Nadiah Ghazalli, M.S.
Graduate Student and a CIRM Predoctoral Scholar
626-256-HOPE (4673), ext. 31235
 
Center for Biomedicine & Genetics
Our Center for Biomedicine & Genetics (CBG) manufactures promising new genetic and cellular agents created by researches for use inclinical trials. We are uniquely equipped to evaluate therapies swiftly and move lifesaving drugs into the marketplace with great speed.
City of Hope has been the home of many illustrious scientists, including six members of the prestigious National Academy of Sciences: Ernest Beutler, Alfred Knudson, Rachmiel Levine, Susumo Ohno, Eugene Roberts, and Arthur Riggs. Learn more about our current scientists and researchers.
Cytogenetics Office Location
City of Hope and Beckman Research Institute 1500 East Duarte Road Duarte, CA 91010-3000 Northwest Building
Room 2265

Phone: 626-256-HOPE (4673), ext. 62025
Fax: 626-301-8877

Biostatistics Office Location
City of Hope and Beckman Research Institute
1500 East Duarte Road
Duarte, CA  91010-3000

Information Sciences Building (#171)

Phone:  626-256-HOPE (4673), Ext. 61444
Fax:  626-471-7106
or 626-301-8802
 
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 


NEWS & UPDATES
  • On Jan. 1, 2015, six City of Hope patients who have journeyed through cancer will welcome the new year with their loved ones atop City of Hope’s Tournament of Roses Parade float. The theme of the float is “Made Possible by HOPE.” The theme of the parade is “Inspiring Stories.” Repr...
  • When 25-year-old Angelina Mattos was diagnosed with Stage 4 oral cancer earlier this year, she learned that her only hope of survival was through the removal of her tongue, a surgery that leaves people without the ability to talk or eat normally, sometimes permanently ending their ability to speak. After hearin...
  • Two years ago, Joselyn Miller and her family sat together as stem cells from her brother’s bone marrow were infused into her – a precious gift of life that the family is excited to have the chance to pass to another patient in need. Today, the stem cell recipient is healthy. Her 23-year-old son Rex, who […...
  • Even as the overall rate of oral cancers in the United States steadily declines, the rate of tongue cancer is increasing — especially among white females ages 18 to 44. An oral cancer diagnosis, although rare, is serious. Only half of the people diagnosed with oral cancer are still alive after five years, accor...
  • Sometimes cancer found in the lungs is not lung cancer at all. It can be another type of cancer that originated elsewhere in the body and spread, or metastasized, to the lungs through the bloodstream or lymphatic system. These tumors are called lung metastases, or metastatic cancer to the lungs, and are not the...
  • When it comes to research into the treatment of hematologic cancers, City of Hope scientists stand out. One study that  they presented this week at the annual meeting of the American Society of Hematology suggests a new standard of care for HIV-associated lymphoma, another offers promise for the treatment of re...
  • Patients with HIV-associated lymphoma may soon have increased access to the current standard of care for some non-HIV infected patients – autologous stem cell transplants. Impressive new data, presented Monday at the annual meeting of the American Society of Hematology (ASH) in San Francisco, indicate that HIV-...
  • On Jan. 1, 2015, six City of Hope patients who have journeyed through cancer will welcome the new year with their loved ones atop City of Hope’s Tournament of Roses Parade float. The theme of the float is “Made Possible by HOPE.” The theme of the Rose Parade is “Inspiring Stories.”...
  • The holidays can create an overwhelming urge to give to people in need — especially to sick children and families spending the holidays in a hospital room. That’s a good thing. Holiday donations of toys and gifts can bolster the spirits, and improve the lives, of people affected by illness, and hospitals ...
  • On Jan. 1, 2015, six City of Hope patients who have journeyed through cancer will welcome the new year with their loved ones atop City of Hope’s Tournament of Roses Parade float. The theme of the float is “Made Possible by HOPE.” The theme of the parade is “Inspiring Stories.” Here...
  • Cancer has a way of “talking” to the immune system and corrupting it to work on its own behalf instead of defending the body. Blocking this communication would allow the immune system to see cancer cells for what they are – something to be fought off – and stop them from growing. A breakthrough Scientists [R...
  • On Jan. 1, 2015, six City of Hope patients who have journeyed through cancer will welcome the new year with their loved ones atop City of Hope’s Tournament of Roses Parade float. The theme of the float is “Made Possible by HOPE.” The theme of the parade is “Inspiring Stories.” By V...
  • On Jan. 1, 2015, six City of Hope patients who have journeyed through cancer will welcome the new year with their loved ones atop City of Hope’s Tournament of Roses Parade float. The theme of the float is “Made Possible by HOPE.” The theme of the parade is “Inspiring Stories.” The ...
  • On Jan. 1, 2015, six City of Hope patients who have journeyed through cancer will welcome the new year with their loved ones atop City of Hope’s Tournament of Roses Parade float. The theme of the float is “Made Possible by HOPE.” The theme of the parade is “Inspiring Stories.” In 2...
  • You’ve done the easy stuff – braved the toy store and the Black Friday frenzy, stayed up all night trolling deals online, picked up gift cards for your colleagues at work. There’s just one gift left, the one you’ve been putting off and the one that means so much. What do you give your friend who […]